By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Trodelvy, in combination with Keytruda, significantly lowers the risk of progression in triple-negative breast cancer by 35%, ...

Drugmaker stocks tend to trade at mid-single-digit multiples of trailing annual sales. Summit has no sales, as ivonescimab is ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Several analysts are hailing Merus as the sure winner in the race to a new treatment for head and neck squamous cell ...

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion in a partnership ...

Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted ...

U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , ...